Intellia Therapeutics, Inc. (NTLA) fell 43.79% to $14.39, down $11.21, after providing an update on its Magnitude Phase 1/2 clinical trials evaluating NTLA-3001 for alpha-1 antitrypsin deficiency or AATD. The company reported that while early-stage data demonstrated successful in vivo gene editing, efficacy signals were lower than expected, prompting a strategic reassessment of the program's next phase.
Intellia said it remains committed to advancing its CRISPR-based therapeutic pipeline but will "prioritize programs with stronger clinical validation and commercial potential." The company plans to provide further updates on development timelines and cost reductions in upcoming quarters.
On Friday, NTLA opened at $23.80, hit a high of $24.15 and a low of $13.91, compared to a previous close of $25.60 on the NasdaqGS. Trading volume soared well above average. The stock's 52-week range is $13.91 - $37.66.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.